Bolt Biotherapeutics (NASDAQ:BOLT) Issues Earnings Results

Bolt Biotherapeutics (NASDAQ:BOLT) released its earnings results on Tuesday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.04), Zacks reports. Bolt Biotherapeutics had a negative return on equity of 64.49% and a negative net margin of 665.56%. The business had revenue of $1.14 million for the quarter, compared to analyst estimates of $1.02 million.

Bolt Biotherapeutics Price Performance

Shares of BOLT stock traded up $0.01 during mid-day trading on Thursday, reaching $0.63. The stock had a trading volume of 9,869 shares, compared to its average volume of 164,873. The company has a market cap of $23.95 million, a P/E ratio of -0.36 and a beta of 0.92. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 0.19. Bolt Biotherapeutics has a 12-month low of $0.55 and a 12-month high of $1.56. The business has a 50-day simple moving average of $0.64 and a 200 day simple moving average of $0.74.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat, Bolt Biotherapeutics has an average rating of “Hold” and a consensus price target of $3.50.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.